The global influenza vaccine market is expected to reach $7471 million by 2028, projecting a CAGR of 6.43% during the forecast period. The base year considered for the study is 2019. The estimated period is between 2020 and 2028. The rising cases of influenza are a crucial driving force for the influenza vaccine market. According to the latest global flu update published by the World Health Organization (WHO), the majority of North America, Asia, and Europe are experiencing increasing incidences of influenza virus from the beginning of 2020.

GLOBAL INFLUENZA VACCINE MARKET FORECAST 2020-2028

Global Influenza Vaccine Market by Type (Quadrivalent Vaccine, Trivalent Vaccine) by Technology (Egg-based Technology, Cell-based Technology) by Age Group (Pediatric Age Group, Adult Age Group)  by Delivery Mode (Injection, Asal Spray) and by Geography.

Request free sample

Report Summary

The global influenza vaccine market is expected to reach $7471 million by 2028, projecting a CAGR of 6.43% during the forecast period. The base year considered for the study is 2019. The estimated period is between 2020 and 2028.

The factors augmenting the global influenza vaccine market growth are:

  • Government immunization programs to eradicate ailments from the society
  • Rise in the cases of influenza
  • Technology advancement
    Influenza Vaccine Market

To learn more about this report, request a free sample copy

The rising cases of influenza are a crucial driving force for the influenza vaccine market. According to the latest global flu update published by the World Health Organization (WHO), the majority of North America, Asia, and Europe are experiencing increasing incidences of influenza virus from the beginning of 2020. Around 68.7% of global lab specimens were of influenza A, whereas 31.3% as influenza B, at the end of December 2019. Influenza B is dominant in the United States and Canada. The majority of Europe is affected by influenza A. Some of the Asian countries are experiencing a continued increase in influenza, which is higher than the previous three flu seasons. Influenza B viruses, 2009 H1N1, and H3N2, are dominant ones in the Asia Pacific region. A significant part of Africa reported moderately increased levels of influenza.

In 2019, the dominant category in the type segment was the Quadrivalent influenza vaccine, contributing around 63.02% of the revenue share, and it is also anticipated to be the fastest-growing influenza vaccine type. Quadrivalent vaccines are designed with a goal to provide broader protection against four viral strains, two in each of A and B strains. Hence, many pharmaceutical companies are manufacturing these vaccines for the upcoming flu seasons. Also, it has a cost-benefit analysis over the other influenza vaccines.

However, the high cost of development and the lengthy process of development are profoundly restricting the growth of the global influenza vaccine market.

The report on the global influenza vaccine market includes the segmentation analysis on the basis of type, technology, age group, delivery mode.

Market by Type:

  • Quadrivalent
  • Trivalent

Market by Technology:

  • Egg-based
  • Trivalent

Market by Age Group:

  • Pediatric
  • Adult

Market by Delivery Mode:

  • Injection
  • Nasal Spray

Geographically, the global Influenza vaccine market has been segmented on the basis of four major regions, which includes:

  • North America: the United States and Canada
  • Europe: the United Kingdom, Germany, France, Italy, Russia, Belgium, Poland, and the Rest of Europe
  • Asia Pacific: China, India, Japan, South Korea Australia & New Zealand, Indonesia, Thailand, Vietnam, and the Rest of Asia Pacific
  • Rest of World: Latin America, the Middle East & Africa

In 2019, North America captured the largest market share of 47.33% in terms of revenue. North America is an important market for the influenza vaccine. Rising cases of influenza during the low-temperature season would be the key driver for the growth of the influenza vaccine market in North America.

The Asia Pacific is the fastest-growing region for the influenza vaccine market. It is mostly due to the high population growth rates, followed by the increasing expenditure on healthcare schemes and improved access to healthcare.

Some of the well-known players of the global Influenza vaccine market are:

  • Merck
  • Novartis AG
  • Pfizer Inc
  • Sanofi
  • CSL Ltd

Key findings of the global influenza vaccine market are:

  • Quadrivalent is the dominant type of influenza vaccine.
  • Cell-based technology is a rapidly growing technology in the market.
  • The adult age group is the dominant sub-segment in the market.

Table of Contents

  1. RESEARCH SCOPE & METHODOLOGY
    • STUDY OBJECTIVES
    • SCOPE OF STUDY
    • METHODOLOGY
    • ASSUMPTIONS & LIMITATIONS
  2. EXECUTIVE SUMMARY
    • MARKET SIZE & ESTIMATES `
    • MARKET OVERVIEW
  3. MARKET DYNAMICS
    • PARENT MARKET ANALYSIS: VACCINE MARKET
    • MARKET DEFINITION
    •    KEY DRIVERS
      • GOVERNMENT IMMUNIZATION PROGRAMS TO ERADICATE AILMENTS FROM THE SOCIETY
      • RISE IN THE CASES OF INFLUENZA
      • TECHNOLOGY ADVANCEMENT
    •    KEY RESTRAINTS
      • HIGH COST OF DEVELOPMENT
      • LENGTHY PROCESS OF DEVELOPMENT
  1. KEY ANALYTICS
    • KEY INVESTMENT INSIGHTS
    •    PORTER’S FIVE FORCE ANALYSIS
      • BUYER POWER
      • SUPPLIER POWER
      • SUBSTITUTION
      • NEW ENTRANTS
      • INDUSTRY RIVALRY
    • OPPORTUNITY MATRIX
    • VENDOR LANDSCAPE
  2. MARKET BY TYPE
    • QUADRIVALENT VACCINE
    • TRIVALENT VACCINE
  3. MARKET BY TECHNOLOGY
    • EGG-BASED TECHNOLOGY
    • CELL-BASED TECHNOLOGY
  4. MARKET BY AGE GROUP
    • PEDIATRIC AGE GROUP
    • ADULT AGE GROUP
  5. MARKET BY DELIVERY MODE
    • INJECTION
    • NASAL SPRAY
  6. GEOGRAPHICAL ANALYSIS
    •    NORTH AMERICA
      • UNITED STATES
      • CANADA
    •    EUROPE
      • UNITED KINGDOM
      • GERMANY
      • FRANCE
      • ITALY
      • RUSSIA
      • BELGIUM
      • POLAND
      • REST OF EUROPE
    •    ASIA PACIFIC
      • CHINA
      • JAPAN
      • INDIA
      • SOUTH KOREA
      • AUSTRALIA & NEW ZEALAND
      • THAILAND
      • INDONESIA
      • VIETNAM
      • REST OF ASIA PACIFIC
    •    REST OF WORLD
      • LATIN AMERICA
      • MIDDLE EAST & AFRICA
  1. COMPANY PROFILES
    • MERCK
    • NOVARTIS AG
    • PFIZER INC
    • SANOFI
    • BIODIEM
    • EMERGENT BIOSOLUTIONS
    • HOFFMANN-LA ROCHE LTD
    • GLAXOSMITHKLINE
    • ABBOTT
    • CSL LTD

TABLE LIST

TABLE 1: MARKET SNAPSHOT – INFLUENZA VACCINE

TABLE 2: GLOBAL INFLUENZA VACCINE MARKET, BY TYPE, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)

TABLE 3: GLOBAL INFLUENZA VACCINE MARKET, BY TYPE, FORECAST YEARS, 2020-2028 (IN $ MILLION)

TABLE 4: GLOBAL QUADRIVALENT VACCINE MARKET, BY REGION, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)

TABLE 5: GLOBAL QUADRIVALENT VACCINE MARKET, BY REGION, FORECAST YEARS, 2020-2028 (IN $ MILLION)

TABLE 6: GLOBAL TRIVALENT VACCINE MARKET, BY REGION, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)

TABLE 7: GLOBAL TRIVALENT VACCINE MARKET, BY REGION, FORECAST YEARS, 2020-2028 (IN $ MILLION)

TABLE 8: GLOBAL INFLUENZA VACCINE MARKET, BY TECHNOLOGY, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)

TABLE 9: GLOBAL INFLUENZA VACCINE MARKET, BY TECHNOLOGY, FORECAST YEARS, 2020-2028 (IN $ MILLION)

TABLE 10: GLOBAL EGG-BASED TECHNOLOGY MARKET, BY REGION, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)

TABLE 11: GLOBAL EGG-BASED TECHNOLOGY MARKET, BY REGION, FORECAST YEARS, 2020-2028 (IN $ MILLION)

TABLE 12: GLOBAL CELL-BASED TECHNOLOGY MARKET, BY REGION, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)

TABLE 13: GLOBAL CELL-BASED TECHNOLOGY MARKET, BY REGION, FORECAST YEARS, 2020-2028 (IN $ MILLION)

TABLE 14: GLOBAL INFLUENZA VACCINE MARKET, BY AGE GROUP, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)

TABLE 15: GLOBAL INFLUENZA VACCINE MARKET, BY AGE GROUP, FORECAST YEARS, 2020-2028 (IN $ MILLION)

TABLE 16: GLOBAL PEDIATRIC AGE GROUP MARKET, BY REGION, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)

TABLE 17: GLOBAL PEDIATRIC AGE GROUP MARKET, BY REGION, FORECAST YEARS, 2020-2028 (IN $ MILLION)

TABLE 18: GLOBAL ADULT AGE GROUP MARKET, BY REGION, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)

TABLE 19: GLOBAL ADULT AGE GROUP MARKET, BY REGION, FORECAST YEARS, 2020-2028 (IN $ MILLION)

TABLE 20: GLOBAL INFLUENZA VACCINE MARKET, BY DELIVERY MODE, HISTORICAL YEARS, 2016-2019 (IN $ MILLION

TABLE 21: GLOBAL INFLUENZA VACCINE MARKET, BY DELIVERY MODE, FORECAST YEARS, 2020-2028 (IN $ MILLION)

TABLE 22: GLOBAL INJECTION MARKET, BY REGION, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)

TABLE 23: GLOBAL INJECTION MARKET, BY REGION, FORECAST YEARS, 2020-2028 (IN $ MILLION)

TABLE 24: GLOBAL NASAL SPRAY MARKET, BY REGION, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)

TABLE 25: GLOBAL NASAL SPRAY MARKET, BY REGION, FORECAST YEARS, 2020-2028 (IN $ MILLION)

TABLE 26: GLOBAL INFLUENZA VACCINE MARKET, BY GEOGRAPHY, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)

TABLE 27: GLOBAL INFLUENZA VACCINE MARKET, BY GEOGRAPHY, FORECAST YEARS, 2020-2028 (IN $ MILLION)

TABLE 28: NORTH AMERICA INFLUENZA VACCINE MARKET, BY COUNTRY, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)

TABLE 29: NORTH AMERICA INFLUENZA VACCINE MARKET, BY COUNTRY, FORECAST YEARS, 2020-2028 (IN $ MILLION)

TABLE 30: EUROPE INFLUENZA VACCINE MARKET, BY COUNTRY, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)

TABLE 31: EUROPE INFLUENZA VACCINE MARKET, BY COUNTRY, FORECAST YEARS, 2020-2028 (IN $ MILLION)

TABLE 32: ASIA PACIFIC INFLUENZA VACCINE MARKET, BY COUNTRY, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)

TABLE 33: ASIA PACIFIC INFLUENZA VACCINE MARKET, BY COUNTRY, FORECAST YEARS, 2020-2028 (IN $ MILLION)

TABLE 34: REST OF WORLD INFLUENZA VACCINE MARKET, BY REGION, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)

TABLE 35: REST OF WORLD INFLUENZA VACCINE MARKET, BY REGION, FORECAST YEARS, 2020-2028 (IN $ MILLION)

FIGURE LIST          

FIGURE 1: KEY INVESTMENT INSIGHTS

FIGURE 2: PORTER’S FIVE FORCE ANALYSIS

FIGURE 3: OPPORTUNITY MATRIX

FIGURE 4: VENDOR LANDSCAPE

FIGURE 5: GLOBAL INFLUENZA VACCINE MARKET, GROWTH POTENTIAL, BY TYPE, IN 2019

FIGURE 6: GLOBAL INFLUENZA VACCINE MARKET, BY QUADRIVALENT VACCINE, 2020-2028 (IN $ MILLION)

FIGURE 7: GLOBAL INFLUENZA VACCINE MARKET, BY TRIVALENT VACCINE, 2020-2028 (IN $ MILLION)

FIGURE 8: GLOBAL INFLUENZA VACCINE MARKET, GROWTH POTENTIAL, BY TECHNOLOGY, IN 2019

FIGURE 9: GLOBAL INFLUENZA VACCINE MARKET, BY EGG-BASED TECHNOLOGY, 2020-2028 (IN $ MILLION)

FIGURE 10: GLOBAL INFLUENZA VACCINE MARKET, BY CELL-BASED TECHNOLOGY, 2020-2028 (IN $ MILLION)

FIGURE 11: GLOBAL INFLUENZA VACCINE MARKET, GROWTH POTENTIAL, BY AGE GROUP, IN 2019

FIGURE 12: GLOBAL INFLUENZA VACCINE MARKET, BY PEDIATRIC AGE GROUP, 2020-2028 (IN $ MILLION)

FIGURE 13: GLOBAL INFLUENZA VACCINE MARKET, BY ADULT AGE GROUP, 2020-2028 (IN $ MILLION)

FIGURE 14: GLOBAL INFLUENZA VACCINE MARKET, GROWTH POTENTIAL, BY DELIVERY MODE, IN 2019

FIGURE 15: GLOBAL INFLUENZA VACCINE MARKET, BY INJECTION, 2020-2028 (IN $ MILLION)

FIGURE 16: GLOBAL INFLUENZA VACCINE MARKET, BY NASAL SPRAY, 2020-2028 (IN $ MILLION)

FIGURE 17: NORTH AMERICA INFLUENZA VACCINE MARKET, REGIONAL OUTLOOK, 2019 & 2028 (IN %)

FIGURE 18: UNITED STATES INFLUENZA VACCINE MARKET, 2020-2028 (IN $ MILLION)

FIGURE 19: CANADA INFLUENZA VACCINE MARKET, 2020-2028 (IN $ MILLION)

FIGURE 20: EUROPE INFLUENZA VACCINE MARKET, REGIONAL OUTLOOK, 2019 & 2028 (IN %)

FIGURE 21: UNITED KINGDOM INFLUENZA VACCINE MARKET, 2020-2028 (IN $ MILLION)

FIGURE 22: GERMANY INFLUENZA VACCINE MARKET, 2020-2028 (IN $ MILLION)

FIGURE 23: FRANCE INFLUENZA VACCINE MARKET, 2020-2028 (IN $ MILLION)

FIGURE 24: ITALY INFLUENZA VACCINE MARKET, 2020-2028 (IN $ MILLION)

FIGURE 25: RUSSIA INFLUENZA VACCINE MARKET, 2020-2028 (IN $ MILLION)

FIGURE 26: BELGIUM INFLUENZA VACCINE MARKET, 2020-2028 (IN $ MILLION)

FIGURE 27: POLAND INFLUENZA VACCINE MARKET, 2020-2028 (IN $ MILLION)

FIGURE 28: REST OF EUROPE INFLUENZA VACCINE MARKET, 2020-2028 (IN $ MILLION)

FIGURE 29: ASIA PACIFIC INFLUENZA VACCINE MARKET, REGIONAL OUTLOOK, 2019 & 2028 (IN %)

FIGURE 30: CHINA INFLUENZA VACCINE MARKET, 2020-2028 (IN $ MILLION)

FIGURE 31: JAPAN INFLUENZA VACCINE MARKET, 2020-2028 (IN $ MILLION)

FIGURE 32: INDIA INFLUENZA VACCINE MARKET, 2020-2028 (IN $ MILLION)

FIGURE 33: SOUTH KOREA INFLUENZA VACCINE MARKET, 2020-2028 (IN $ MILLION)

FIGURE 34: AUSTRALIA & NEW ZEALAND INFLUENZA VACCINE MARKET, 2020-2028 (IN $ MILLION)

FIGURE 35: THAILAND INFLUENZA VACCINE MARKET, 2020-2028 (IN $ MILLION)

FIGURE 36: INDONESIA INFLUENZA VACCINE MARKET, 2020-2028 (IN $ MILLION)

FIGURE 37: VIETNAM INFLUENZA VACCINE MARKET, 2020-2028 (IN $ MILLION)

FIGURE 38: REST OF ASIA PACIFIC INFLUENZA VACCINE MARKET, 2020-2028 (IN $ MILLION)

FIGURE 39: REST OF WORLD INFLUENZA VACCINE MARKET, REGIONAL OUTLOOK, 2019 & 2028 (IN %)

FIGURE 40: LATIN AMERICA INFLUENZA VACCINE MARKET, 2020-2028 (IN $ MILLION)

FIGURE 41: MIDDLE EAST & AFRICA INFLUENZA VACCINE MARKET, 2020-2028 (IN $ MILLION)

Segmentation

  1. MARKET BY TYPE
    • QUADRIVALENT VACCINE
    • TRIVALENT VACCINE
  2. MARKET BY TECHNOLOGY
    • EGG-BASED TECHNOLOGY
    • CELL-BASED TECHNOLOGY
  3. MARKET BY AGE GROUP
    • PEDIATRIC AGE GROUP
    • ADULT AGE GROUP
  4. MARKET BY DELIVERY MODE
    • INJECTION
    • NASAL SPRAY
  5. GEOGRAPHICAL ANALYSIS
    •    NORTH AMERICA
      • UNITED STATES
      • CANADA
    •    EUROPE
      • UNITED KINGDOM
      • GERMANY
      • FRANCE
      • ITALY
      • RUSSIA
      • BELGIUM
      • POLAND
      • REST OF EUROPE
    •    ASIA PACIFIC
      • CHINA
      • JAPAN
      • INDIA
      • SOUTH KOREA
      • AUSTRALIA & NEW ZEALAND
      • THAILAND
      • INDONESIA
      • VIETNAM
      • REST OF ASIA PACIFIC
    •    REST OF WORLD
      • LATIN AMERICA
      • MIDDLE EAST & AFRICA

Request Free Sample

To request a free sample copy of this report, please complete the form below :

We offer 10% free customization including country-level data, niche applications and competitive landscape with every report.

    Choose License Type

    Get In Touch

    Inquire Before Buying

    Customization

    Inkwood Research delivers customized reports as per the client's requirement to provide them with an edge in the competitive market

    Request Customization

    RELATED REPORTS